{"product_id":"production-of-plasma-proteins-for-therapeutic-use-isbn-9780470924310","title":"Production of Plasma Proteins for Therapeutic Use","description":"\u003cp\u003e\u003cb\u003eSets forth the state of the science and technology in plasma protein production\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eWith contributions from an international team of eighty leading experts and pioneers in the field, \u003ci\u003eProduction of Plasma Proteins for Therapeutic Use\u003c\/i\u003e presents a comprehensive overview of the current state of knowledge about the function, use, and production of blood plasma proteins. In addition to details of the operational requirements for the production of plasma derivatives, the book describes the biology, development, research, manufacture, and clinical indications of essentially all plasma proteins with established clinical use or therapeutic potential. \u003c\/p\u003e\u003cp\u003e\u003ci\u003eProduction of Plasma Proteins for Therapeutic Use\u003c\/i\u003e covers the key aspects of the plasma fractionation industry in five sections: \u003c\/p\u003e\u003cul\u003e \u003cli\u003e\n\u003cb\u003eSection 1: Introduction to Plasma Fractionation\u003c\/b\u003e initially describes the history of transfusion and then covers the emergence of plasma collection and fractionation from its earliest days to the present time, with the commercial and not-for-profit sectors developing into a multi-billion dollar industry.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 2: Plasma Proteins for Therapeutic Use\u003c\/b\u003e contains 24 chapters dedicated to specific plasma proteins, including coagulation factors, albumin, immunoglobulin, and a comprehensive range of other plasma-derived proteins with therapeutic indications. Each chapter discusses the physiology, biochemistry, mechanism of action, and manufacture of each plasma protein including viral safety issues and clinical uses.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 3: Pathogen Safety of Plasma Products\u003c\/b\u003e examines issues and procedures for enhancing viral safety and reducing the risk of transmissible spongiform encephalopathy transmission.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 4: The Pharmaceutical Environment Applied to Plasma Fractionation\u003c\/b\u003e details the requirements and activities associated with plasma collection, quality assurance, compliance with regulatory requirements, provision of medical affairs support, and the manufacture of plasma products.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 5: The Market for Plasma Products and the Economics of Fractionation\u003c\/b\u003e reviews the commercial environment and economics of the plasma fractionation industry including future trends, highlighting regions such as Asia, which have the potential to exert a major influence on the plasma fractionation industry in the twenty-first century.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ePreface ix\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Introduction to Plasma Fractionation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 The History and Development of the Plasma Protein Fractionation Industry 3\u003cbr\u003e\u003ci\u003eJohn Curling, Neil Goss, and Joseph Bertolini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Plasma Proteins for Therapeutic Use\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2 Production and Clinical Profile of Human Plasma Coagulation Factor VIII 31\u003cbr\u003e\u003ci\u003eSami Chtourou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Production and Clinical Profile of Human Plasma-Derived Von Willebrand Factor 41\u003cbr\u003e\u003ci\u003eSami Chtourou and Michel Poulle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Factor Eight Inhibitor Bypassing Activity 49\u003cbr\u003e\u003ci\u003ePeter Turecek and Hans Peter Schwarz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Prothrombin Complex 65\u003cbr\u003e\u003ci\u003eJürgen Römisch and Katharina Pock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Factor IX 81\u003cbr\u003e\u003ci\u003eSalvador Grancha, Steven Herring, Antonio Páez, Pere Ristol, and Juan Ignacio Jorquera\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Factor XI 93\u003cbr\u003e\u003ci\u003eSami Chtourou and Michel Poulle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Factor XIII and Factor X 101\u003cbr\u003e\u003ci\u003ePeter Feldman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Fibrinogen: Science and Biotechnology 117\u003cbr\u003e\u003ci\u003eGerard Marx\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Fibrin Glues and Bandages 137\u003cbr\u003e\u003ci\u003eHans Christian Hedrich and Heinz Gulle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Production and Clinical Use of Plasma Antithrombin III 147\u003cbr\u003e\u003ci\u003eAndrea Morelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Human Serum Albumin: A Multifunctional Plasma Protein 159\u003cbr\u003e\u003ci\u003eJohn More and Mark Bulmer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Intravenous Immunoglobulin G from Human Plasma – Purification Concepts and Important Quality Criteria 185\u003cbr\u003e\u003ci\u003eAndrea Buchacher and Waltraud Kaar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Hyperimmune Immunoglobulin G 207\u003cbr\u003eHugh Price, Maurice Genereux, and Christopher Sinclair\u003c\/p\u003e \u003cp\u003e15 Rh (D) Immunoglobulin 217\u003cbr\u003e\u003ci\u003eMaurice Genereux, Jodi Smith, William Bees, and Christopher Sinclair\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Alpha 1 -Proteinase Inhibitor: The Disease, the Protein, and Commercial Production 227\u003cbr\u003e\u003ci\u003eWytold Lebing\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 C1-Inhibitor 241\u003cbr\u003e\u003ci\u003eJan Over, Christine Kramer, Anky Koenderman, Diana Wouters, and Sacha Zeerleder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Acid-Stabilized Plasmin as a Novel Direct-Acting Thrombolytic 259\u003cbr\u003e\u003ci\u003eValery Novokhatny, James Rebbeor, Philip Scuderi, and Stephen Petteway Jr.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Reconstituted, Plasma-Derived High-Density Lipoprotein 273\u003cbr\u003e\u003ci\u003ePeter Lerch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Plant-Derived Manufacturing of Apolipoprotein AI Milano : Purification and Functional Characterization 283\u003cbr\u003e\u003ci\u003eCory Nykiforuk, Yin Shen, Elizabeth Murray, Joseph Boothe, and Maurice Moloney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Transferrin 301\u003cbr\u003e\u003ci\u003eLeni von Bonsdorff, Hennie ter Hart, Ingrid Prins-de Nijs, Anky Koenderman, Jan Over, and Jaakko Parkkinen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Plasminogen: Its Role in the Therapy of Ligneous Conjunctivitis 311\u003cbr\u003e\u003ci\u003eClaudia Nardini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Haptoglobin 321\u003cbr\u003e\u003ci\u003eJoan Dalton and Azubuike Okemefuna\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Ceruloplasmin: Biology, Manufacture, and Clinical Use 337\u003cbr\u003e\u003ci\u003eAron Berkovsky and Vladimir Vaschenko\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Solvent\/Detergent Plasma 345\u003cbr\u003e\u003ci\u003eTor-Einar Svae, Andrea Heger, Lothar Biesert, Andrea Neisser-Svae, and Wolfgang Frenzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Pathogen Safety of Plasma Products\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e26 Ensuring Virus Safety of Plasma Products 361\u003cbr\u003e\u003ci\u003eHerbert Dichtelmüller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Transmissible Spongiform Encephalopathies and Plasma Products 369\u003cbr\u003e\u003ci\u003eLuisa Gregori, David Asher, and Dorothy Scott\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 The Pharmaceutical Environment Applied To Plasma Fractionation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e28 Quality Assurance Requirements in Plasma Product Manufacture 383\u003cbr\u003e\u003ci\u003eJens Jesse\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Regulatory Activities Associated with Production and Commercialization of Plasma Protein Therapeutics 403\u003cbr\u003e\u003ci\u003eNancy Kirschbaum and Timothy Lee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 The Emerging Role of Global Medical Affairs in the Twenty-First Century 413\u003cbr\u003e\u003ci\u003eHartmut Ehrlich, David Perry, David Gelmont, and Ramin Farhood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Plasma for Fractionation 423\u003cbr\u003e\u003ci\u003eJoseph Bertolini and Timothy Hayes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 The Pharmaceutical Manufacturing Environment 437\u003cbr\u003e\u003ci\u003eErnst Hetzl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 5 The Market for Plasma Products and the Economics of Fractionation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e33 The Economics of Plasma Fractionation 451\u003cbr\u003e\u003ci\u003eNeil Goss and John Curling\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Future Trends in the Plasma Products Market 461\u003cbr\u003e\u003ci\u003ePaolo Marcucci\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 471\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003csmall\u003eJOSEPH BERTOLINI, BS\u003c\/small\u003ec\u003csmall\u003e (HONS.), MSC, PHD,\u003c\/small\u003e\u003c\/b\u003e is R\u0026amp;D Manager at CSL Bioplasma where he has been closely involved in the technical development and improvement of immunoglobulin and albumin products. He is active in national and international conferences and industry organizations and is a strong advocate for the advancement of bioprocessing. \u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003csmall\u003eNEIL GOSS, BS\u003c\/small\u003ec\u003csmall\u003e (HONS.), PHD,\u003c\/small\u003e\u003c\/b\u003e is Executive Director at Further Options Pty Ltd., a consulting company specializing in biotechnology and the plasma fractionation industry. He was previously Director of R\u0026amp;D, CSL Bioplasma and is the founding organizer for both the Plasma Product Biotechnology Meeting series and the BioProcessing Network. \u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003csmall\u003eJOHN CURLING, BS\u003c\/small\u003ec\u003csmall\u003e, \u003c\/small\u003e\u003c\/b\u003eis a consultant in bioseparations and protein purification whose clients have included numerous biopharmaceutical, biotechnology, and vendor companies. He pioneered the development of chromatographic methods of plasma fractionation and was the President of the Process Separation Division of Pharmacia. He has acted as an advisor to the World Health Organization.    \u003c\/p\u003e\u003cp\u003e\u003cb\u003eSets forth the state of the science and technology in plasma protein production\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eWith contributions from an international team of eighty leading experts and pioneers in the field, \u003ci\u003eProduction of Plasma Proteins for Therapeutic Use\u003c\/i\u003e presents a comprehensive overview of the current state of knowledge about the function, use, and production of blood plasma proteins. In addition to details of the operational requirements for the production of plasma derivatives, the book describes the biology, development, research, manufacture, and clinical indications of essentially all plasma proteins with established clinical use or therapeutic potential. \u003c\/p\u003e\u003cp\u003e\u003ci\u003eProduction of Plasma Proteins for Therapeutic Use\u003c\/i\u003e covers the key aspects of the plasma fractionation industry in five sections: \u003c\/p\u003e\u003cul\u003e \u003cli\u003e\n\u003cb\u003eSection 1: Introduction to Plasma Fractionation\u003c\/b\u003e initially describes the history of transfusion and then covers the emergence of plasma collection and fractionation from its earliest days to the present time, with the commercial and not-for-profit sectors developing into a multi-billion dollar industry.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 2: Plasma Proteins for Therapeutic Use\u003c\/b\u003e contains 24 chapters dedicated to specific plasma proteins, including coagulation factors, albumin, immunoglobulin, and a comprehensive range of other plasma-derived proteins with therapeutic indications. Each chapter discusses the physiology, biochemistry, mechanism of action, and manufacture of each plasma protein including viral safety issues and clinical uses.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 3: Pathogen Safety of Plasma Products\u003c\/b\u003e examines issues and procedures for enhancing viral safety and reducing the risk of transmissible spongiform encephalopathy transmission.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 4: The Pharmaceutical Environment Applied to Plasma Fractionation\u003c\/b\u003e details the requirements and activities associated with plasma collection, quality assurance, compliance with regulatory requirements, provision of medical affairs support, and the manufacture of plasma products.\u003c\/li\u003e \u003cli\u003e\n\u003cb\u003eSection 5: The Market for Plasma Products and the Economics of Fractionation\u003c\/b\u003e reviews the commercial environment and economics of the plasma fractionation industry including future trends, highlighting regions such as Asia, which have the potential to exert a major influence on the plasma fractionation industry in the twenty-first century.\u003c\/li\u003e \u003c\/ul\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989864038629,"sku":"NP9780470924310","price":176.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470924310.jpg?v=1761785719","url":"https:\/\/k12savings.com\/products\/production-of-plasma-proteins-for-therapeutic-use-isbn-9780470924310","provider":"K12savings","version":"1.0","type":"link"}